{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T20:30:17Z","timestamp":1787689817466,"version":"build-2784847793"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The diagnosis of hereditary angioedema with a normal C1Inh was genetic. The two most frequent pathogenic variants are found in\n                      <jats:italic>the<\/jats:italic>\n                      FXII and PLG genes. Their management is similar to that of HAE patients with C1Inh deficiency but without evidence-based medicine.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The French Reference Centre for Angioedema (CREAK) Our center identified all patients with HAE with a normal C1Inh to evaluate their therapeutic management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a national retrospective study conducted in our center the CREAK network.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 287 patients were identified with an\n                      <jats:italic>F12<\/jats:italic>\n                      pathogenic variant (133 families), 38 with\n                      <jats:italic>PLG<\/jats:italic>\n                      (12 families) and one patient with\n                      <jats:italic>KNG1<\/jats:italic>\n                      . Among these patients, 111 patients with HAE-FXII and 19 patients with HAE-PLG were symptomatic. More women than men were symptomatic (86.3% vs. 30.8%, respectively) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090,0001). The mean age at first attack was 24\u2009\u00b1\u200912 years. 49% of patients with HAE-FXII were estrogen dependent (vs. 0% HAE-PLG,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090,01). 91% of patients with HAE-PLG needed to receive at least one attack of icatibant with 100% efficacy. 67% of patients with HAE-FXII were treated at least once: 56% with icatibant and 54% with C1Inh concentrate (during pregnancy). 12,6% of patients with HAE-FXII and 47,4% of patients with HAE-PLG required long-term prophylactic treatment: 66,7% of patients HAE-PLG who were taking tranexamic acid were attack-free (vs. 37,5 3% of HAE-FXII patients). 100% of patients with HAE-FXII treated with lanadelumab were completely asymptomatic (vs. 25% of patients with HAE-PLG).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>HAE patients with a normal C1inh have specific clinical features, including a later age at first attack than HAE patients with a normal C1inh, high sensitivity to estrogens of HAE-FXII and the location of the HAE-PLG on the tongue. The treatments used for HAE patients with C1Inh deficiency appear to be effective and safe. Low-dose progestin-only pills are good contraceptive options.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-04155-8","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T19:35:15Z","timestamp":1764704115000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Management of hereditary angioedema with normal C1Inh: a series of 163 French patients"],"prefix":"10.1186","volume":"21","author":[{"given":"Alexis","family":"Bocquet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8245-4767","authenticated-orcid":false,"given":"Laurence","family":"Bouillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaelle","family":"Hardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Boccon-Gibod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alban","family":"Deroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Arnaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Pelletier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie Du","family":"Thanh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Ozanne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Armengol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre Yves","family":"Jeandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Sailler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Caroline","family":"Taquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Launay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Fain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Gobert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"issue":"9225","key":"4155_CR1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0140-6736(00)02483-1","volume":"356","author":"K -Bork","year":"2000","unstructured":"Bork K, Barnstedt SE, Koch P, Traupe H. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet. 2000;356(9225):213\u20137.","journal-title":"Lancet"},{"issue":"2","key":"4155_CR2","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/all.13076","volume":"72","author":"K -Bork","year":"2017","unstructured":"Bork K, Wulff K, Witzke G, Hardt J. Treatment for hereditary angioedema with normal C1-INH and specific mutations in the F12 gene(HAE-FXII). Allergy. 2017;72(2):320\u201332.","journal-title":"Allergy"},{"issue":"4","key":"4155_CR3","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.jaip.2017.09.025","volume":"6","author":"CL -Veronez","year":"2018","unstructured":"Veronez CL, Moreno AS, Constantino-Silva RN, Maia LSM, Ferriani MPL, Castro FFM, et al. Hereditary angioedema with normal C1 inhibitor and F12 mutations in 42 Brazilian families. J Allergy Clin Immunol Pract. 2018;6(4):1209\u201316.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"4155_CR4","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/cei.12820","volume":"185","author":"A -Deroux","year":"2016","unstructured":"Deroux A, Boccon-Gibod I, Fain O, Pralong P, Ollivier Y, Pagnier A, et al. Hereditary angioedema with normal C1 inhibitor and factor XII mutation: a series of 57 patients from the French National center of reference for angioedema. Clin Exp Immunol. 2016;185(3):332\u20137.","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"4155_CR5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.anai.2012.05.022","volume":"109","author":"C -Marcos","year":"2012","unstructured":"Marcos C, L\u00f3pez Lera A, Varela S, Li\u00f1ares T, Alvarez-Eire MG, L\u00f3pez-Trascasa M. Clinical, biochemical, and genetic characterization of type III hereditary angioedema in 13 Northwest Spanish families. Ann Allergy Asthma Immunol. 2012;109(3):195\u2013200.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"4155_CR6","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/all.13270","volume":"73","author":"K -Bork","year":"2018","unstructured":"Bork K, Wulff K, Steinm\u00fcller-Magin L, Braenne I, Staubach-Renz P, Witzke G, Hardt J. Hereditary angioedema with a mutation in the plasminogen gene. Allergy. 2018;73(2):442\u201350.","journal-title":"Allergy"},{"issue":"11","key":"4155_CR7","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1111\/all.13543","volume":"73","author":"A -Belb\u00e9zier","year":"2018","unstructured":"Belb\u00e9zier A, Hardy G, Marlu R, Defendi F, Dumestre Perard C, Boccon-Gibod I, Launay D, Bouillet L. Plasminogen gene mutation with normal C1 inhibitor hereditary angioedema: three additional French families. Allergy. 2018;73(11):2237\u20139.","journal-title":"Allergy"},{"issue":"12","key":"4155_CR8","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1111\/all.13869","volume":"74","author":"K -Bork","year":"2019","unstructured":"Bork K, Wulff K, Rossmann H, Steinm\u00fcller-Magin L, Braenne I, Witzke G, Hardt J. Hereditary angioedema cosegregating with a novel kininogen 1 gene mutation changing the N-terminal cleavage site of Bradykinin. Allergy. 2019;74(12):2479\u201381.","journal-title":"Allergy"},{"issue":"4","key":"4155_CR9","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.jaci.2021.01.011","volume":"148","author":"K -Bork","year":"2021","unstructured":"Bork K, Wulff K, M\u00f6hl BS, Steinm\u00fcller-Magin L, Witzke G, Hardt J, Meinke P. Novel hereditary angioedema linked with a Heparan sulfate 3-O-sulfotransferase 6 gene mutation. J Allergy Clin Immunol. 2021;148(4):1041\u20138.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"4155_CR10","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.jaci.2017.05.020","volume":"141","author":"V -Bafunno","year":"2018","unstructured":"Bafunno V, Firinu D, D\u2019Apolito M, Cordisco G, Loffredo S, Leccese A, et al. Mutation of the angiopoietin-1 gene (ANGPT1) associates with a new type of hereditary angioedema. J Allergy Clin Immunol. 2018;141(3):1009\u201317.","journal-title":"J Allergy Clin Immunol"},{"key":"4155_CR11","doi-asserted-by":"crossref","unstructured":"Ariano A, D\u2019Apolito M, Bova M, Bellanti F, Loffredo S, D\u2019Andrea G et al. A myoferlin gain-of-function variant associates with a new type of hereditary angioedema. Allergy. 2020;75(11):2989\u20132992.","DOI":"10.1111\/all.14454"},{"key":"4155_CR12","doi-asserted-by":"publisher","first-page":"106080","DOI":"10.1016\/j.intimp.2019.106080","volume":"78","author":"A -Gompel","year":"2020","unstructured":"Gompel A, Fain O, Boccon-Gibod I, Gobert D, Bouillet L. Exogenous hormones and hereditary angioedema. Int Immunopharmacol. 2020;78:106080.","journal-title":"Int Immunopharmacol"},{"key":"4155_CR13","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1016\/j.jaci.2016.02.021","volume":"138","author":"S -de Maat","year":"2016","unstructured":"de Maat S, Bj\u00f6rkqvist J, Suffritti C, Wiesenekker C, Nagtegaal W, Koekman A, et al. Plasmin is a natural trigger for Bradykinin production in patients with hereditary angioedema with factor XII mutations. J Allergy Clin Immunol. 2016;138:1414\u2013e14239.","journal-title":"J Allergy Clin Immunol"},{"key":"4155_CR14","doi-asserted-by":"publisher","first-page":"1090732","DOI":"10.3389\/fphys.2022.1090732","volume":"13","author":"S -Hintze","year":"2023","unstructured":"Hintze S, M\u00f6hl B, Beyerl J, Wulff K, Wieser A, Bork K, Meinke P. Mutant plasminogen in hereditary angioedema is bypassing FXII\/kallikrein to generate Bradykinin. Front Physiol. 2023;13:1090732.","journal-title":"Front Physiol"},{"issue":"4","key":"4155_CR15","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.anai.2013.07.012","volume":"111","author":"L -Bouillet","year":"2013","unstructured":"Bouillet L, Launay D, Fain O, Boccon-Gibod I, Laurent J, Martin L, et al. Hereditary angioedema with C1 inhibitor deficiency: clinical presentation and quality of life of 193 French patients. Ann Allergy Asthma Immunol. 2013;111(4):290\u20134.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"4155_CR16","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.clim.2015.02.013","volume":"157","author":"D -Firinu","year":"2015","unstructured":"Firinu D, Bafunno V, Vecchione G, Barca MP, Manconi PE, Santacroce R, et al. Characterization of patients with angioedema without wheals: the importance of F12 screening. Clin Immunol. 2015;157(2):239\u201348.","journal-title":"Clin Immunol"},{"issue":"5","key":"4155_CR17","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.anai.2016.09.001","volume":"117","author":"M -Pi\u00f1ero-Saavedra","year":"2016","unstructured":"Pi\u00f1ero-Saavedra M, Gonz\u00e1lez-Quevedo T, Saenz de San Pedro B, Alcaraz C, Bobadilla-Gonz\u00e1lez P, Fern\u00e1ndez-Vieira L, Hinojosa B, Garc\u00eda-Lozano R. Hereditary angioedema with F12 mutation: clinical features and enzyme polymorphisms in 9 Southwestern Spanish families. Ann Allergy Asthma Immunol. 2016;117(5):520\u20136.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"4155_CR18","doi-asserted-by":"crossref","unstructured":"Bouillet L, Fain O, Armengol G, Aubineau M, Blanchard-Delaunay C, Dalmas MC et al. Long-term prophylaxis in hereditary angioedema management: Current practices in France and unmet needs. Allergy Asthma Proc. 2022; 43(5):406\u2013412.","DOI":"10.2500\/aap.2022.43.220046"},{"key":"4155_CR19","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.jaip.2017.03.017","volume":"5","author":"S -Hudey","year":"2017","unstructured":"Hudey S, Westermann-Clark E, Lockey R. Cardiovascular and diabetic medications that cause Bradykinin-Mediated angioedema. J Allergy Clin Immunol Pract. 2017;5:610\u20135.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"4155_CR20","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1001\/2013.jamainternmed.34","volume":"172","author":"S -Toh","year":"2012","unstructured":"Toh S, Reichman ME, Houstoun M, Ross Southworth M, Ding X, Hernandez AF, et al. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. Arch Intern Med. 2012;172:1582\u20139.","journal-title":"Arch Intern Med"},{"key":"4155_CR21","doi-asserted-by":"publisher","first-page":"914376","DOI":"10.3389\/fgene.2022.914376","volume":"13","author":"CM -Mathey","year":"2022","unstructured":"Mathey CM, Maj C, Scheer AB, Fazaal J, Wedi B, Wieczorek D, et al. Molecular genetic screening in patients with ACE Inhibitor\/Angiotensin receptor Blocker-Induced angioedema to explore the role of hereditary angioedema genes. Front Genet. 2022;13:914376.","journal-title":"Front Genet"},{"issue":"1","key":"4155_CR22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/iid3.137","volume":"5","author":"L -Bouillet","year":"2017","unstructured":"Bouillet L, Boccon-Gibod I, Launay D, Gompel A, Kanny G, Fabien V, Fain O, IOS Study Group. Hereditary angioedema with normal C1 inhibitor in a French cohort: clinical characteristics and response to treatment with Icatibant. Immun Inflamm Dis. 2017;5(1):29\u201336.","journal-title":"Immun Inflamm Dis"},{"issue":"1","key":"4155_CR23","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/cei.12379","volume":"178","author":"C -Wintenberger","year":"2014","unstructured":"Wintenberger C, Boccon-Gibod I, Launay D, et al. Tranexamic acid as maintenance treatment for nonhistaminergic angioedema: analysis of efficacy and safety in 37 patients. Clin Exp Immunol. 2014;178(1):112\u20137.","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"4155_CR24","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.anai.2021.05.028","volume":"127","author":"L -Bouillet","year":"2021","unstructured":"Bouillet L, Bocquet A, Belbezier A, Boccon-Gibod I. Effectiveness of lanadelumab in patients with hereditary angioedema with normal C1 inhibitor and FXII mutation. Ann Allergy Asthma Immunol. 2021;127(3):391\u20132.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"4155_CR25","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/cea.12055","volume":"43","author":"C -Saule","year":"2013","unstructured":"Saule C, Boccon-Gibod I, Fain O, et al. Benefits of progestin contraception in nonallergic angioedema. Clin Exp Allergy. 2013;43(4):475\u201382.","journal-title":"Clin Exp Allergy"},{"issue":"9","key":"4155_CR26","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1111\/ene.15423","volume":"29","author":"L -Hoisnard","year":"2022","unstructured":"Hoisnard L, Laanani M, Passeri T, Duranteau L, Coste J, Zureik M, Froelich S, Weill A. Risk of intracranial meningioma with three potent progestogens: A population-based case\u2013control study. Eur J Neurol. 2022;29(9):2801\u20139.","journal-title":"Eur J Neurol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04155-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-04155-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04155-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T14:27:16Z","timestamp":1767709636000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-025-04155-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4155"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-04155-8","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"assertion":[{"value":"13 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients signed a consent form for the genetic study to be carried out. We have followed the reference methodology for the processing of personal data in the context of research not involving the human person (MR-004): Written information was given to patients when their information was entered into the HAE with normal C1INH study. Oral consent was obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AB has consulted\/ served as speaker for, engaged in research and educational projects with or accepted travel grants from the following companies: BioCryst, and Takeda. LB has consulted\/ served as speaker for, engaged in research and educational projects with or accepted travel grants from the following companies: BioCryst, CSL Behring, Takeda and kalvista. GH has consulted\/ served as speaker for Biocryst and takeda. GH has consulted\/ served as speaker for Biocryst and takeda. IBG receipt of grants\/research supports from Takeda, Biocryst, Pharming, CSL Behring, Pharvaris, Kalvista, Novartis. Receipt of honoraria or consultation fees from Takeda, Biocryst, Pharming, CSL Behring, Pharvaris, Kalvista, Novartis. AD: none. MA: none. FP: Receipt of honoraria or consultation fees from Takeda, CSL Behring; accepted travel grants from Biocryst. ADT: speaker and\/or principal investigator or subinvestigator and\/or expert for Biocryst and Takeda. NO accepted travel grants from Biocryst. GA: Receipt of honoraria or consultation fees and accepted travel grants from Takeda and Biocryst. PYJ: none. MCT: Receipt of honoraria or consultation fees and accepted travel grants from Takeda, biocryst, Amgen, Novartis. SG: None. LS: none. DL has consulted\/ served as speaker for, engaged in research and educational projects with or accepted travel grants from the following companies Takeda, CSL Behring, Biocryst. OFain has consulted\/ served as speaker for, engaged in research and educational projects with or accepted travel grants from the following companies: BioCryst, CSL Behring, Kalvista and Takeda. DGobert has consulted\/ served as speaker for, engaged in research and educational projects with or accepted travel grants from the following companies: BioCryst, CSL Behring, Kalvista and Takeda.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}